5 Key Takeaways

• 1

  The AGA updated guidelines for moderate-to-severe ulcerative colitis include evidence from seven new therapeutic agents since 2020.

• 2

  Advanced therapies like infliximab and vedolizumab are recommended as first-line options for biologic-naïve patients.

• 3

  For patients previously treated with advanced therapies, high-efficacy options such as tofacitinib are encouraged.

• 4

  Safety findings indicate vedolizumab reduces infection risk and TNF antagonists elevate lymphoma risk.

• 5

  The guidelines will be updated every six months to incorporate new data on therapies and safety findings.